TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Some sub-analysis has shown anthracycline-based regimens are not effective in Her-2 negative
breast cancer, while capecitabine is more effective in this group of patients.
This is a prospective, randomised phase III trial, to compare the efficacy and safety
profiles of two types of adjuvant chemotherapy regimens for HER2 negative, node positive
breast cancer patients.
Control Arm: This includes 6 cycles of TAC 75/50/500 mg/m2 day 1 every 3 weeks. Experimental
Arm: This includes 6 cycles of TC 75/500 mg/m2, day 1 every 3 weeks, concurrently with
capecitabine 950 mg/m2, twice a day, via oral intake, for 14 days, and then a one-week rest
period.
Women with hormone receptor positive tumours must receive 5 years endocrine after the end of
chemotherapy.
Patients may receive radiotherapy when clinically indicated.